Celularity Inc. Reports 52.6% Revenue Decline and Increased Operational Losses in Q2 2025

Celularity Inc. reported a significant decline in its financial performance for the second quarter of 2025, as detailed in its latest 10-Q filing. The company generated total net revenues of $5.736 million for the three months ended June 30, 2025, a decrease of 52.6% compared to $12.111 million in the same period last year. This decline was primarily driven by a 76.1% drop in product sales, which fell from $9.963 million to $2.379 million, largely due to reduced sales of its Biovance 3L product. In contrast, revenues from licenses, royalties, and other sources increased by 139.3%, contributing $2.082 million to the total.

Operating expenses for the second quarter of 2025 were $21.6 million, a slight decrease of 3.1% from $22.286 million in the prior year. The cost of revenues increased significantly, particularly in product sales, which saw costs rise to $2.550 million from $1.119 million, reflecting a write-off of capitalized bulk material costs. The company reported a loss from operations of $15.864 million, compared to a loss of $10.175 million in the same quarter of 2024, marking a 55.9% increase in operational losses.

In terms of strategic developments, Celularity completed the acquisition of Sequence LifeScience's Rebound™ product in October 2024, which is expected to enhance its portfolio of placental-derived biomaterials. The company has also entered into various agreements, including a multi-year research collaboration with Regeneron Pharmaceuticals, which is anticipated to generate additional revenue streams. However, the company continues to face challenges, including a significant accumulated deficit of $944.025 million as of June 30, 2025, and ongoing liquidity concerns.

Operationally, Celularity's total assets decreased to $120.283 million from $132.682 million at the end of 2024, while total liabilities increased to $145.780 million. The company has been actively seeking additional capital to support its operations, as it has incurred substantial losses since its inception. As of June 30, 2025, Celularity had approximately $6.3 million in current debt outstanding, with most of its debt subject to forbearance agreements. The company is under pressure to regain compliance with Nasdaq listing requirements, having received a notice of non-compliance due to late filings.

Looking ahead, Celularity's management has indicated that it will continue to explore opportunities for capital raising and strategic partnerships to support its ongoing operations and product development. The company is focused on advancing its biomaterials and cell therapy product candidates, with plans to submit regulatory filings for new products in the coming years. However, the ability to execute these plans remains contingent on securing sufficient funding and navigating the complexities of the biotechnology market.